Latest Breaking News On - Giacomo chiesi - Page 9 : comparemela.com

Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting

Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nordrhein westfalenUnited kingdomUnited statesInternational centerChiesi groupchiesiNicole muscholFabry diseasefabryNathalie guffonGiacomo chiesiResearch meetingB corpPreference centreUs food drug administrationChiesi groupUniversity medical center hamburgGlobal rare diseases

Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living.

Nordrhein westfalenUnited kingdomUnited statesInternational centerAdam daleyNicole muscholNathalie guffonGiacomo chiesiResearch meetingB corpPreference centreBerry company public relationsChiesi groupUniversity medical center hamburgGlobal rare diseasesChiesi global rare diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected.

United statesUnited kingdomHa afonDror bashanAdam daleyChiesi farmaceuticiGiacomo chiesiChuck padalaProtalix biotherapeutics incB corpEuropean commissionDrug administrationExchange commissionPfizer incBerry company public relationsChiesi group

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChiesi groupchiesiChiesi farmaceuticiGiacomo chiesiB corpGroup chiesiInternational society for mannosidosis related disordersDrug administrationMedia contactjenna urbanberry company public relationsChiesi groupEuropean commission for lamzedeGlobal rare diseasesChiesi global rareEuropean commissionMark stark

First FDA approval of enzyme replacement therapy for AM

The first and only enzyme replacement therapy approved for alpha-mannosidosis in the US has been cleared for adult and paediatric patients.

Giacomo chiesiEuropean medicines agencyChiesi groupDrug administrationCommittee for medicinal products human useEuropean commission for lamzedeChiesi global rare diseasesMedicinal productsHuman useEuropean commission